

Correction: Safety and immunogenicity of an inactivated virus particle vaccine for SARS-CoV-2, BIV1-CovIran: findings from double-blind, randomised, placebo-controlled, phase I and II clinical trials among healthy adults

Mohraz M, Salehi M, Tabarsi P, *et al.* Safety and immunogenicity of an inactivated virus particle vaccine for SARS-CoV-2, BIV1-CovIran: findings from double-blind, randomised, placebo-controlled, phase I and II clinical trials among healthy adults. *BMJ Open* 2022;12:e056872. doi: 10.1136/bmjopen-2021-056872

In the corrected version of the article, the competing interest statements for authors Hamed Hosseini, Minoo Mohraz, and Payam Tabaris have been changed. The original article indicated they had no competing interests. It now states the following:

HH: as manager of the Clinical Trial Center (CTC), an academic CRO affiliated with Tehran University of Medical Sciences, Tehran, Iran, I was responsible for the conduct and monitoring of clinical trials. I was a non-voting member of the Data Safety Monitoring Board, as mandated by the national regulatory authority.

MM: a research contract between Shifapharmed (sponsor) and Iranian Research Centre for HIV/AIDS (IRCHA) for supervising all clinical trial activities of phases one and two has been signed for 1575 million Iranian rials, which has been deposited into the account number of this centre at Tehran University of Medical Sciences. My position at the time was director of this centre; as such, the payment appears to be transferred to my name in Shifa's financial statements.

PT: I had the role of principal investigator in another vaccine project (Spikogen).

The funding statement was corrected to include the organisations of which Shifa is a part. The funding statement previously stated, "The project was funded by Shifa Pharmed Industrial Group". It now states, "The project was funded by Shifa Pharmed Industrial Group. Shifa Pharmed is a part of Barkat Pharmaceutical Group, which belongs to EIKO/Setad".

A sentence of the conclusion was overstated. It said, "Administration of the two shots of 5 µg dose BIV1-CovIran vaccine with a 28-day interval would enhance the immunity of all vaccine recipients against SARS-CoV-2 with no vaccine-related SAEs. The conclusion now says, "Administration of the two shots of 5 µg dose BIV1-CovIran vaccine with a 28-day interval has demonstrated the potential to enhance the immunity of vaccine recipients against SARS-CoV-2 with no serious vaccine-related SAEs". The remainder of the concluding remarks are accurate.

A tracked changes online supplemental file 1 is appended to the paper for transparency.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

BMJ Open 2022;12:e056872corr1. doi:10.1136/bmjopen-2021-056872corr1

